复方苦参注射液是一种广泛应用于临床的纯中药制剂,由苦参、白土苓等中草药提取加工而成,主要含苦参碱、氧化苦参碱等有效成分,近年来其在抗头颈部恶性肿瘤(head and neck carcinoma,HNC)中的应用越来越受到关注。本文就复方苦参注射液...复方苦参注射液是一种广泛应用于临床的纯中药制剂,由苦参、白土苓等中草药提取加工而成,主要含苦参碱、氧化苦参碱等有效成分,近年来其在抗头颈部恶性肿瘤(head and neck carcinoma,HNC)中的应用越来越受到关注。本文就复方苦参注射液与放化疗联合应用的增效减毒、增强免疫系统保护作用、缓解癌性疼痛等临床应用,及其抑制肿瘤细胞增殖、阻滞肿瘤细胞周期、促进肿瘤细胞凋亡、逆转肿瘤细胞耐药性等作用机制进行综述,探讨其在头颈部恶性肿瘤中的应用价值。展开更多
目的探讨染色体维持蛋白(MCM)在头颈癌中的表达和预后治疗效果,旨在为头颈癌潜在的生物标志物以及治疗靶点提供更多的证据。方法使用Oncomine、GEPIA和Human Protein Atlas在线数据库分析MCM在头颈癌中的表达差异;运用GeneMANIA和STRIN...目的探讨染色体维持蛋白(MCM)在头颈癌中的表达和预后治疗效果,旨在为头颈癌潜在的生物标志物以及治疗靶点提供更多的证据。方法使用Oncomine、GEPIA和Human Protein Atlas在线数据库分析MCM在头颈癌中的表达差异;运用GeneMANIA和STRING在线平台预测并构建MCM蛋白质相互作用网络;通过Metascape数据库对MCM进行功能和通路富集分析;通过Kaplan-Meier plotter分析平台研究MCM在头颈癌中的预后价值;使用Timer在线工具完成MCM与头颈癌中的免疫浸润细胞的相关性研究。结果头颈癌中MCM2/3/4/5/6/7/8/10的mRNA表达较正常头颈部组织显著增加(P<0.01),其中MCM2/3/7在转录和翻译阶段均过表达。MCM2-MCM7与DNA复制密切相关,并且发现细胞周期相关基因与MCM复合体密切相关。功能和通路富集分析表明其生物学功能主要与DNA复制和cGMP-PKG信号通路有关。MCM1/3/5/6/10的高表达与头颈癌患者总生存期的改善明显相关(P<0.05)。此外,人类乳头瘤病毒(HPV)感染状态对MCM基因家族的表达会造成一定影响,头颈鳞癌HPV阳性(HNSCC-HPV-pos)中MCM的表达与免疫浸润的丰度显著相关,尤其是B细胞、CD8^(+)T细胞和CD4^(+)T细胞。HNSCC-HPV-pos亚组的B细胞、CD8^(+)T细胞和中性粒细胞免疫浸润明显增加(P<0.05),这与MCM的表达水平有关。结论MCM2/3/7的异常高表达提示其在头颈癌发生发展中起重要作用。MCM1/3/5/6/10可作为判断头颈癌患者生存率的候选预后标志物。展开更多
Photoimmunotherapy (PIT), developed by the National Cancer Institute, involves Cetuximab sarotalocan sodium infusion followed by laser irradiation. PIT exerts specific antitumor effects on a variety of carcinomas that...Photoimmunotherapy (PIT), developed by the National Cancer Institute, involves Cetuximab sarotalocan sodium infusion followed by laser irradiation. PIT exerts specific antitumor effects on a variety of carcinomas that express epidermal growth factor receptors. PIT is a new cancer treatment option approved by Japan ahead of other countries worldwide. As of 2022, PIT is indicated in “unresectable, locally advanced, or locally recurrent head and neck cancer, with priority given to standard treatments such as chemotherapy when available”. The conventional treatment for unresectable locally advanced or locally recurrent head and neck cancer is palliative. Whether photoimmunotherapy can be curative for unresectable locally advanced head and neck cancers depends on the case. Herein, we report a case of locally recurrent nasopharyngeal carcinoma, treated with photoimmunotherapy via the nasal cavity, along with a literature review. Preoperative simulation provided considerable information on device selection, numbers of devices, and availability of working space. As a result, a complete response was obtained following a cylindrical diffuser puncture. Cases of local recurrence of nasopharyngeal carcinoma are considered a good indication for PIT. However, since the follow-up period after treatment was short in this case, we will continue to conduct strict follow-ups and accumulate more cases.展开更多
文摘复方苦参注射液是一种广泛应用于临床的纯中药制剂,由苦参、白土苓等中草药提取加工而成,主要含苦参碱、氧化苦参碱等有效成分,近年来其在抗头颈部恶性肿瘤(head and neck carcinoma,HNC)中的应用越来越受到关注。本文就复方苦参注射液与放化疗联合应用的增效减毒、增强免疫系统保护作用、缓解癌性疼痛等临床应用,及其抑制肿瘤细胞增殖、阻滞肿瘤细胞周期、促进肿瘤细胞凋亡、逆转肿瘤细胞耐药性等作用机制进行综述,探讨其在头颈部恶性肿瘤中的应用价值。
文摘目的探讨染色体维持蛋白(MCM)在头颈癌中的表达和预后治疗效果,旨在为头颈癌潜在的生物标志物以及治疗靶点提供更多的证据。方法使用Oncomine、GEPIA和Human Protein Atlas在线数据库分析MCM在头颈癌中的表达差异;运用GeneMANIA和STRING在线平台预测并构建MCM蛋白质相互作用网络;通过Metascape数据库对MCM进行功能和通路富集分析;通过Kaplan-Meier plotter分析平台研究MCM在头颈癌中的预后价值;使用Timer在线工具完成MCM与头颈癌中的免疫浸润细胞的相关性研究。结果头颈癌中MCM2/3/4/5/6/7/8/10的mRNA表达较正常头颈部组织显著增加(P<0.01),其中MCM2/3/7在转录和翻译阶段均过表达。MCM2-MCM7与DNA复制密切相关,并且发现细胞周期相关基因与MCM复合体密切相关。功能和通路富集分析表明其生物学功能主要与DNA复制和cGMP-PKG信号通路有关。MCM1/3/5/6/10的高表达与头颈癌患者总生存期的改善明显相关(P<0.05)。此外,人类乳头瘤病毒(HPV)感染状态对MCM基因家族的表达会造成一定影响,头颈鳞癌HPV阳性(HNSCC-HPV-pos)中MCM的表达与免疫浸润的丰度显著相关,尤其是B细胞、CD8^(+)T细胞和CD4^(+)T细胞。HNSCC-HPV-pos亚组的B细胞、CD8^(+)T细胞和中性粒细胞免疫浸润明显增加(P<0.05),这与MCM的表达水平有关。结论MCM2/3/7的异常高表达提示其在头颈癌发生发展中起重要作用。MCM1/3/5/6/10可作为判断头颈癌患者生存率的候选预后标志物。
文摘Photoimmunotherapy (PIT), developed by the National Cancer Institute, involves Cetuximab sarotalocan sodium infusion followed by laser irradiation. PIT exerts specific antitumor effects on a variety of carcinomas that express epidermal growth factor receptors. PIT is a new cancer treatment option approved by Japan ahead of other countries worldwide. As of 2022, PIT is indicated in “unresectable, locally advanced, or locally recurrent head and neck cancer, with priority given to standard treatments such as chemotherapy when available”. The conventional treatment for unresectable locally advanced or locally recurrent head and neck cancer is palliative. Whether photoimmunotherapy can be curative for unresectable locally advanced head and neck cancers depends on the case. Herein, we report a case of locally recurrent nasopharyngeal carcinoma, treated with photoimmunotherapy via the nasal cavity, along with a literature review. Preoperative simulation provided considerable information on device selection, numbers of devices, and availability of working space. As a result, a complete response was obtained following a cylindrical diffuser puncture. Cases of local recurrence of nasopharyngeal carcinoma are considered a good indication for PIT. However, since the follow-up period after treatment was short in this case, we will continue to conduct strict follow-ups and accumulate more cases.
